Breaking News


Phase IIa results for WBI-1001 atopic dermatitis cream


Positive results from a phase IIa clinical trial testing two concentrations (0.5% and 1.0%) of WBI-1001, a new, nonsteroidal, topical cream treatment for atopic dermatitis (AD), showed that both cream concentrations were superior to placebo in deceasing AD, with an excellent safety profile. The clinical phase IIa trial for WBI-1001 was a randomized, double-blind, placebo-controlled study conducted in Montreal with the objectives of evaluating the safety and efficacy of the cream on topically treated patients. A total of 36 patients with mild to moderate AD were treated with 0.5% or 1% of WBI-1001 cream or placebo twice daily for 28 days. No serious side effects were reported in any of the ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list